Stockscreener 앱 받기
50.77
3.44%
1.695
전일 마감가:
$49.07
열려 있는:
$49.36
하루 거래량:
5.30M
Relative Volume:
0.37
시가총액:
$224.56B
수익:
$50.91B
순이익/손실:
$18.95B
주가수익비율:
11.91
EPS:
4.261
순현금흐름:
$1.92B
1주 성능:
+3.82%
1개월 성능:
+15.57%
6개월 성능:
-11.13%
1년 성능:
-24.49%
1일 변동 폭
$49.36
$51.00
1주일 범위
$48.29
$51.00
52주 변동 폭
$35.12
$71.80
노보 노디스크 Stock (NVO) Company Profile
Compare NVO vs LLY, JNJ, ABBV, MRK, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
50.75 | 218.05B | 50.91B | 18.95B | 1.92B | 4.261 |
LLY
Lilly Eli Co
|
1,147.85 | 1.05T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
251.30 | 620.51B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
247.31 | 438.16B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
123.40 | 306.33B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
151.31 | 292.64B | 54.66B | 13.58B | 16.05B | 7.0171 |
노보 노디스크 Stock (NVO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-26 | 개시 | Wolfe Research | Peer Perform |
| 2026-03-18 | 개시 | Bernstein | Outperform |
| 2026-03-10 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2026-03-03 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2026-03-02 | 다운그레이드 | Goldman | Buy → Neutral |
| 2026-02-24 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2026-02-24 | 다운그레이드 | Kepler | Buy → Hold |
| 2026-02-23 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2026-02-12 | 업그레이드 | Jefferies | Underperform → Hold |
| 2026-01-27 | 개시 | Citigroup | Neutral |
| 2025-12-08 | 다운그레이드 | Argus | Buy → Hold |
| 2025-10-27 | 재개 | Jefferies | Underperform |
| 2025-10-01 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2025-09-29 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2025-09-17 | 업그레이드 | Berenberg | Hold → Buy |
| 2025-09-16 | 업그레이드 | Rothschild & Co Redburn | Neutral → Buy |
| 2025-09-09 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2025-08-13 | 업그레이드 | BNP Paribas Exane | Underperform → Neutral |
| 2025-08-05 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-07-31 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2025-07-30 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-04-17 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2025-03-13 | 업그레이드 | Kepler | Hold → Buy |
| 2025-03-03 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-02-12 | 개시 | Morgan Stanley | Equal-Weight |
| 2025-01-06 | 업그레이드 | Bernstein | Underperform → Mkt Perform |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-04-12 | 개시 | BMO Capital Markets | Outperform |
| 2024-01-23 | 개시 | Morgan Stanley | Overweight |
| 2024-01-16 | 재개 | UBS | Neutral |
| 2023-12-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-02 | 개시 | Argus | Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2022-07-15 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-06-28 | 다운그레이드 | UBS | Neutral → Sell |
| 2022-06-27 | 업그레이드 | Exane BNP Paribas | Underperform → Neutral |
| 2022-06-07 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-05-31 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-04-25 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2022-04-12 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2022-03-16 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2022-01-25 | 다운그레이드 | Liberum | Hold → Sell |
| 2021-12-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-12-17 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2021-01-20 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2021-01-15 | 개시 | Deutsche Bank | Buy |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-07-06 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-05-11 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-05-04 | 개시 | Cowen | Market Perform |
| 2020-03-16 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2020-01-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-11-18 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-09-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-08-30 | 다운그레이드 | Jefferies | Hold → Underperform |
| 2019-06-20 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2019-06-11 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2019-04-29 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-01-29 | 개시 | Exane BNP Paribas | Outperform |
| 2018-12-11 | 재개 | Jefferies | Hold |
| 2018-10-09 | 개시 | Guggenheim | Buy |
| 2017-12-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2017-12-06 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2017-12-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-09-25 | 다운그레이드 | Exane BNP Paribas | Outperform → Neutral |
| 2017-09-06 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
모두보기
노보 노디스크 주식(NVO)의 최신 뉴스
Is This Disturbing Trend Bad News for Eli Lilly in the Billion-Dollar Obesity Drug Market? - The Motley Fool
NVO Stock Quote Price and Forecast - CNN
Novo Nordisk A/Sshare repurchase programme - Finansavisen
Novo Nordisk (NYSE:NVO) Updates Wegovy Label In Singapore With 21% Weight Loss Data - Sahm
Total equity of Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B – BCBA:NVOD - TradingView
Weekly Recap: NOVO_B MAR buyback and Shares jump after UK Wegovy approval - TradingView
Novo Nordisk (NVO) Wins UK Wegovy Pill Approval As Medicare Opens GLP 1 Access - Sahm
NVONovo Nordisk ADR Options - Finviz
Market news - investments.halifax.co.uk
European ADRs Slid In US Trading On Wednesday - Finimize
Novo Nordisk holds analyst rating, JPMorgan reiterates Neutral on the shares - Ad-hoc-news.de
Novo Nordisk consensus picture, shares backed by strong obesity demand - Ad-hoc-news.de
NOVA Forecast — Price Target — Prediction for 2027 - TradingView
NVO Forecast — Price Target — Prediction for 2027 - TradingView
Novo Nordisk consensus shifts after analyst moves, shares trade lower in Europe - AD HOC NEWS
Novo Nordisk A/S ADR B Unsponsored Brazilian Depositary Receipt Repr 0.125 ADR B - TradingView
Novo Nordisk consensus after Morningstar downgrade, shares remain in focus on NYSE and Copenhagen - Ad-hoc-news.de
NVO/N Forecast — Price Target — Prediction for 2027 - TradingView
Non-controlling/minority interest of Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B – BCBA:NVOC - TradingView
Novo Nordisk (NYSE: NVO) repurchases 20,959,179 shares in 2026 - Stock Titan
Novo Nordisk updates analyst targets, shares stay in S&P 500 focus - AD HOC NEWS
Novo Nordisk Stock Is Surging Monday: What's Driving The Action? - Sahm
Novo Nordisk wins key South Africa ruling, shares extend obesity-drug lead - Ad-hoc-news.de
Wegovy from Novo Nordisk A/ S (ADR)weekly injection reshapes obesity care - AD HOC NEWS
European ADRs Open The Week Higher In US Trading - Finimize
Novo Nordisk StockAnalyst consensus and GLP-1 momentum - AD HOC NEWS
Novo Nordisk (NYSE:NVO) Faces Cyber Breach While Pushing Oral Wegovy Into China - Sahm
Why Novo Nordisk’s Wegovy weekly injection changes daily routines - AD HOC NEWS
노보 노디스크 (NVO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.99%
자본화:
|
볼륨(24시간):